(A and B) ATAC-seq results of human leukemia K562+Vector, +WT (wild-type
SLFN11) and +E669Q (putative ATPase-dead SLFN11) (Murai et al., 2018) without or with drug treatments
(no treatment [control], 1,000 nM CPT treatment for 4 h). (A) Dot plots
representing ATAC peak quantification (x axis) before and after CPT treatment (y
axis). Each dot corresponds to a single ATAC peak (n = 18,088; note that 189,
239, and 212 data points are outside the axis limits for K562+Vector, +WT, and
+E669Q, respectively). (B) Bar graphs representing ATAC peak quantification
(FPKM) at promoter and intergenic regions (mean ± SEM). The number of
ATAC peak of each region is shown in parentheses. ***p ≤ 0.001.
(C) Bar graphs of qRT-PCR for the indicated genes and treatments (250 nM
CPT, 10 nM CHK1i, or 100 nM CHK1i) in K562-Vector, -WT, -E669Q cells. Each
transcript was normalized to the expression level of 18S RNA. Results are the
average of three independent experiments with ± SD. *p ≤ 0.05, **p
≤ 0.01, ***p ≤ 0.001 (two-tailed unpaired t test). See also Table S5.